Propanc Biopharma (PPCB) has a reason to get excited.
With a promising treatment for solid tumor cancers coming down its pipeline, the early stage healthcare company has its sights set on changing the way cancer is treated.
CEO James Nathanielsz told TheStreet at the LD Micro conference in Los Angeles that his firm is in the right place to develop treatment for the kind of tumor that affects 8% of cancer patients.
Nathanielsz also explained how Propanc is restructuring its debt in order to stoke optimism in investors while the company's most promising drug is still in development.
For more from the LD Micro Conference in La: